NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced preliminary unaudited product revenue growth of 163% to a record $9.1 million for the fiscal year ended September 30, 2025, compared to $3.5 million in fiscal 2024. The medical technology company, focused on improving surgical care options for neurological disorders, also reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025.
This substantial revenue growth demonstrates the increasing adoption of NeuroOne's technology in treating neurological conditions, particularly epilepsy. The company attributed the performance to expanded customer interest and positive outcomes with the OneRF® Ablation system for patients suffering from seizures associated with epilepsy. According to CEO Dave Rosa, "We believe we are well positioned to expand use of the OneRF technology platform."
The significance of this growth extends beyond financial metrics, representing progress in addressing critical healthcare challenges. Epilepsy affects millions worldwide, and improved treatment options could substantially enhance patient quality of life while potentially reducing healthcare costs. The company's technology focuses on minimally invasive solutions for EEG recording, brain stimulation, and ablation procedures for various neurological disorders including Parkinson's disease, dystonia, essential tremors, and chronic pain from failed back surgeries.
Complete financial results for the quarter are expected to be announced in December 2025. The company emphasized that these preliminary unaudited results are subject to completion of accounting and interim review procedures and may be adjusted. Investors should exercise caution and not draw inferences beyond the provided information, as this preliminary financial data should not substitute for full financial statements prepared according to U.S. generally accepted accounting principles.
NeuroOne will host a virtual investor webinar on October 7, 2025, at 8:30 a.m. Eastern Standard Time to discuss business operations and recent updates. The event will feature CEO Dave Rosa providing a business overview and CFO Ron McClurg presenting financial details. Participants can access the webinar through the NMTC Virtual Webinar Link or by dialing 888-506-0062 (U.S.) or 973-528-0011 (international) with access code 619723.
The company's progress in neurological treatment technology comes at a time when advancements in medical devices for brain disorders are increasingly important. With potential applications extending to depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence, NeuroOne's growth trajectory suggests broader implications for neurological care innovation. The recorded revenue performance indicates growing clinical acceptance of their approach to improving patient outcomes while potentially reducing procedural costs in neurological treatments.
